Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02591446 · ClinicalTrials.gov registry record

Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders

A clinical trial, sponsored by Rhode Island Hospital.

Completed
Registry status
48
Enrollment target

NCT02591446 is a clinical trial that has completed, run by Rhode Island Hospital. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02591446 has completed, sponsored by Rhode Island Hospital.

COMPLETED
Registry status
48 participants
Enrollment target

Study Summary

Autism Spectrum Disorder (ASD) is the most prevalent of the developmental disorders and their incidence is rising. However, the variability in the behavioral symptoms is large. In part for these reasons, the ASD clinical diagnosis is challenging and often is not made until 3-5 years of age. Thus, there remains an unmet need for a valid and reliable marker which would facilitate ASD diagnosis early in life, enable efficient study of ASD risk factors, and eventually serve as a useful marker to inform the development of effective therapies and assess treatment response in future clinical trials. The specific brain based marker that investigators are currently evaluating is brain plasticity (the changes that occur in your brain through experience). Investigators measure brain plasticity using noninvasive brain stimulation including transcranial magnetic stimulation (TMS) combined with brain imaging, EEG, and behavioral outcome measures. Their work to date demonstrates the potential utility of these techniques in higher-functioning adolescents and adults with ASD, and pilot data support the feasibility and safety of applying the same measures to children and lower functioning individuals. In this study, investigators will evaluate the validity of this marker in low- and high-functioning adults with ASD, in low- and high-functioning children with ASD, and assess the reliability of this marker.

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-10
Est. Completion 2017-08-07

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT02591446

The ClinicalTrials.gov registry entry for NCT02591446 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02591446 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02591446 about?

NCT02591446 is a clinical study titled "Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders". Autism Spectrum Disorder (ASD) is the most prevalent of the developmental disorders and their incidence is rising. However, the variability in the behavioral symptoms is large. In part for these reasons, the ASD clinical diagnosis is challenging and often is not made until 3-5 years of age. Thus, th...

What is the current status of trial NCT02591446?

This trial is currently completed. The enrollment target is 48 participants. The study started on 2014-10. Estimated completion is 2017-08-07.

Who is sponsoring clinical trial NCT02591446?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.